neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: GlobeNewswire
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name ???®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China, the trade name is ???® meaning “Excellent Allergy (treatment) Fast”. ARS Pharma and Pediatrix Therapeutics anticipate filing for approv
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
SPRY
Earnings
- 11/10/25 - Miss
SPRY
Sec Filings
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- SPRY's page on the SEC website